RxDoctor Payments Data

Armen Moughamian, MD

Neurology · San Francisco, CANPI 1932527306

Payments from drug & device makers

$1,260,165in general payments, 2019–2025

Across 584 payments — averaging $2157.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alnylam Pharmaceuticals Inc.$295K
  • Eli Lilly$286K
  • Lilly USA, LLC$256K
  • Eisai Inc.$204K
  • Biogen$171K
  • Eisai CO., LTD.$30K
  • plus $17K from 5 others
$2,016in research payments, 2019–2025

Across 3 payments — averaging $672.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$2K

What the payments were for

  • Consulting fees$190,86834%
  • Speaking & faculty fees$288,58052%
  • Travel & lodging$66,08612%
  • Food & beverage$8,6072%
  • Education$20%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,260,165 in reported general payments places this provider in the 95th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$158,055
Medicare patients
409
Services billed
991

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
IngrezzaValbenazine Tosylate12$86,607
Rivastigmine65$11,638
Donepezil Hcl762$9,427
Aripiprazole95$7,097
Memantine Hcl151$6,431
Carbidopa-LevodopaCarbidopa/Levodopa102$4,530
Quetiapine Fumarate137$3,703
Escitalopram Oxalate272$3,246
Carbidopa-Levodopa ErCarbidopa/Levodopa24$1,253
Levetiracetam34$821
Trazodone Hcl83$817
Olanzapine34$783
Mirtazapine38$602
Lamotrigine20$425
Gabapentin16$326

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCOlanzapine$256,450$78334 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,996 neurology providers in California.

Other neurology in San Francisco

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →